A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1–2 Oral Anti-Diabetic Drugs

INTRODUCTION: Once-weekly semaglutide is a new glucagon-like peptide-1 (GLP-1) analogue administered at a 1.0 or 0.5 mg dose. As head-to-head trials assessing once-weekly semaglutide as an add-on to 1–2 oral anti-diabetic drugs (OADs) vs other GLP-1 receptor agonists (GLP-1 RAs) are limited, a netwo...

Descripción completa

Detalles Bibliográficos
Autores principales: Witkowski, Michal, Wilkinson, Lars, Webb, Neil, Weids, Alan, Glah, Divina, Vrazic, Hrvoje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984927/
https://www.ncbi.nlm.nih.gov/pubmed/29675798
http://dx.doi.org/10.1007/s13300-018-0424-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984927/
https://www.ncbi.nlm.nih.gov/pubmed/29675798
http://dx.doi.org/10.1007/s13300-018-0424-2

Ejemplares similares